About Aytu BioScience (NASDAQ:AYTU)
Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. Further, the company provides Fiera personal care device, a hands-free wearable product for women that is designed to enhance interest in and physical readiness for sex. Aytu BioScience, Inc. is based in Englewood, Colorado.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AYTU
CUSIPN/A
Phone720-437-6580
Debt
Debt-to-Equity RatioN/A
Current Ratio1.61%
Quick Ratio1.33%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.22 million
Price / Sales0.97
Cash FlowN/A
Price / CashN/A
Book Value$4.84 per share
Price / Book0.12
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-22,500,000.00
Net Margins-419.34%
Return on Equity-295.55%
Return on Assets-91.13%
Miscellaneous
Employees63
Outstanding Shares5,600,000
Aytu BioScience (NASDAQ:AYTU) Frequently Asked Questions
What is Aytu BioScience's stock symbol?
Aytu BioScience trades on the NASDAQ under the ticker symbol "AYTU."
When did Aytu BioScience's stock split? How did Aytu BioScience's stock split work?
Shares of Aytu BioScience reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu BioScience stock prior to the reverse split would have 5 shares after the split.
How were Aytu BioScience's earnings last quarter?
Aytu BioScience (NASDAQ:AYTU) released its quarterly earnings results on Friday, February, 9th. The company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($1.78) by $0.89. The company earned $1.05 million during the quarter. Aytu BioScience had a negative net margin of 419.34% and a negative return on equity of 295.55%. View Aytu BioScience's Earnings History.
What price target have analysts set for AYTU?
1 analysts have issued 1-year price targets for Aytu BioScience's stock. Their forecasts range from $3.00 to $3.00. On average, they expect Aytu BioScience's share price to reach $3.00 in the next twelve months. View Analyst Ratings for Aytu BioScience.
Are investors shorting Aytu BioScience?
Aytu BioScience saw a decline in short interest during the month of April. As of April 13th, there was short interest totalling 265,333 shares, a decline of 49.0% from the March 30th total of 520,739 shares. Based on an average trading volume of 2,779,015 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.0% of the shares of the company are short sold.
Who are some of Aytu BioScience's key competitors?
Some companies that are related to Aytu BioScience include OHR Pharmaceutical (OHRP), Endonovo Therapeutics (ENDV), RXi Pharmaceuticals (RXII), EpiCept (IMNP), MabVax Therapeutics (MBVX), Immune Therapeutics (IMUN), Acura Pharmaceuticals (ACUR), Marina Biotech (MRNA), EyeGate Pharma (EYEG), Onconova Therapeutics (ONTX), Uluru (ULUR), MusclePharm (MSLP), Dare Bioscience (DARE), International Stem Cell (ISCO) and Sunwin Tech Group (SUWN).
Who are Aytu BioScience's key executives?
Aytu BioScience's management team includes the folowing people:
- Mr. Joshua R. Disbrow, Chairman, CEO & Pres (Age 43)
- Mr. Jarrett T. Disbrow Ph.D., Chief Operating Officer (Age 43)
- Mr. David A. Green, CFO, Principal Accounting Officer, Sec. & Treasurer (Age 55)
Has Aytu BioScience been receiving favorable news coverage?
Media coverage about AYTU stock has trended somewhat positive recently, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aytu BioScience earned a daily sentiment score of 0.13 on Accern's scale. They also gave media headlines about the company an impact score of 45.98 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Aytu BioScience?
Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aytu BioScience's stock price today?
One share of AYTU stock can currently be purchased for approximately $0.56.
How big of a company is Aytu BioScience?
Aytu BioScience has a market capitalization of $3.19 million and generates $3.22 million in revenue each year. Aytu BioScience employs 63 workers across the globe.
How can I contact Aytu BioScience?
Aytu BioScience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]
MarketBeat Community Rating for Aytu BioScience (AYTU)
MarketBeat's community ratings are surveys of what our community members think about Aytu BioScience and other stocks. Vote "Outperform" if you believe AYTU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AYTU will underperform the S&P 500 over the long term. You may vote once every thirty days.
Aytu BioScience (NASDAQ:AYTU) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Aytu BioScience in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 435.71%. The high price target for AYTU is $3.00 and the low price target for AYTU is $3.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.00 | $3.00 | $3.00 | $3.00 |
| Price Target Upside: | 435.71% upside | 421.83% upside | 421.83% upside | 421.83% upside |
Aytu BioScience (NASDAQ:AYTU) Consensus Price Target History
Aytu BioScience (NASDAQ:AYTU) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/6/2017 | HC Wainwright | Set Price Target | Buy | $3.00 | N/A |  |
| 2/17/2017 | Taglich Brothers | Reiterated Rating | Speculative Buy | | N/A | |
| 9/26/2016 | Rodman & Renshaw | Initiated Coverage | Buy | $9.00 | N/A | |
(Data available from 4/25/2016 forward)
Aytu BioScience (NASDAQ:AYTU) Earnings History and Estimates Chart
Aytu BioScience (NASDAQ AYTU) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/9/2018 | Q2 2018 | ($1.78) | ($0.89) | | $1.05 million | View | N/A | |
| 11/9/2017 | Q1 2018 | ($7.60) | ($1.76) | | $1.08 million | View | N/A | |
| 8/31/2017 | Q4 2017 | ($12.00) | ($4.16) | | $0.84 million | View | N/A | |
| 5/11/2017 | Q3 2017 | ($0.28) | ($0.48) | $1.08 million | $0.89 million | View | N/A | |
| 2/9/2017 | 12/31/2016 | ($0.52) | ($0.55) | $1.11 million | $0.79 million | View | N/A | |
| 11/7/2016 | Q1 2017 | ($0.84) | ($1.17) | $1.20 million | $0.70 million | View | N/A | |
| 9/1/2016 | Q4 2016 | ($15.60) | ($45.40) | $0.70 million | $0.94 million | View | N/A | |
| 5/11/2016 | Q3 2016 | | ($93.64) | | $0.67 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Aytu BioScience (NASDAQ:AYTU) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Aytu BioScience (NASDAQ AYTU) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 17.80%
Institutional Ownership Percentage: 7.35%
Aytu BioScience (NASDAQ AYTU) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/6/2018 | David A Green | CFO | Buy | 66,600 | $0.45 | $29,970.00 | | |
| 3/6/2018 | Jarrett Disbrow | COO | Buy | 226,105 | $0.45 | $101,747.25 | | |
| 1/20/2016 | Joshua R Disbrow | CEO | Buy | 153,846 | $0.65 | $99,999.90 | 153,846 | |
(Data available from 1/1/2013 forward)
Aytu BioScience (NASDAQ AYTU) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | AYTU- Now That The Stock Dilution Has Passed, It's Time To Pay Attention To One Of The Safest And Most Effective APPROVED Testosterone Drugs On The Market, Natesto.
seekingalpha.com - April 14 at 3:51 PM |
 | Aytu BioScience to Present at The MicroCap Conference on April 10th in New York City at the Essex House
finance.yahoo.com - April 3 at 10:08 AM |
| Aytu BioScience Announces Exercise of Underwriters' Over-Allotment Option
finance.yahoo.com - March 28 at 10:03 AM |
| Aytu BioScience Presents New Research Findings for Natesto(R) at the Endocrine Society's 100th Annual Meeting
finance.yahoo.com - March 20 at 9:58 AM |
| Has Aytu BioScience Inc (NASDAQ:AYTU) Improved Earnings Growth In Recent Times?
finance.yahoo.com - March 9 at 10:40 AM |
 | BRIEF-Bigger Capital Fund Reports 7.4 Pct Passive Stake In Aytu Bioscience As Of March 2
www.reuters.com - March 8 at 4:58 PM |
 | Form 4 AYTU BIOSCIENCE, INC For: Mar 06 Filed by: Disbrow Jarrett
www.streetinsider.com - March 8 at 10:10 AM |
 | Aytu Bioscience Inc (AYTU) CFO David A. Green Acquires 66,600 Shares
www.americanbankingnews.com - March 7 at 7:46 PM |
| Insider Buying: Aytu Bioscience Inc (AYTU) COO Buys 226,105 Shares of Stock
www.americanbankingnews.com - March 7 at 7:15 PM |
| Aytu BioScience Receives Market Registration for the MiOXSYS® System for Male Infertility in Mexico
finance.yahoo.com - March 7 at 9:55 AM |
| Aytu BioScience Announces Closing of $12,000,000 Public Offering
finance.yahoo.com - March 6 at 4:35 PM |
| Aytu Bioscience (AYTU) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 9 at 11:02 AM |
| Aytu BioScience Provides Fiscal Second Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
finance.yahoo.com - February 8 at 4:35 PM |
| Aytu BioScience to Report Fiscal Second Quarter 2018 Results and Business Update
finance.yahoo.com - February 1 at 9:02 AM |
| Aytu Bioscience (AYTU) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - January 31 at 2:10 AM |
| Is Aytu BioScience Inc’s (NASDAQ:AYTU) Liquidity As Good As Its Solvency?
finance.yahoo.com - January 2 at 10:29 AM |
| Aytu BioScience, Inc. to Present at the 10th Annual LD Micro Main Event
finance.yahoo.com - November 29 at 10:48 AM |
| Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.
finance.yahoo.com - November 28 at 11:15 AM |
| Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017
finance.yahoo.com - November 28 at 11:15 AM |
| BRIEF-Aytu Bioscience files for mixed shelf of upto $100 mln
www.reuters.com - November 22 at 10:00 PM |
| AYTU BIOSCIENCE, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - November 16 at 8:55 PM |
| Q1 2017 Aytu BioScience Inc Earnings Release - Time Not Supplied
biz.yahoo.com - November 7 at 1:40 PM |
| AYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statemen
biz.yahoo.com - November 2 at 10:18 PM |
 | Aytu BioScience Further Demonstrates Clinical Utility for MiOXSYS™ System as an Aid in the Diagnosis of Male Infertility
www.prnewswire.com - November 1 at 9:11 PM |
| Aytu BioScience to Present at Two Upcoming Investor Conferences
www.prnewswire.com - September 14 at 3:43 PM |
| Q4 2016 Aytu BioScience Inc Earnings Release - Time Not Supplied
biz.yahoo.com - September 1 at 12:09 PM |
| AYTU BIOSCIENCE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - September 1 at 12:09 PM |
| Acerus Pharmaceuticals' (TRLPF) CEO Tom Rossi on Q2 2016 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 4:48 PM |
| AYTU BIOSCIENCE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Secu
biz.yahoo.com - August 2 at 8:29 AM |
 | Testosterone replacement treatment is opportunity for Colorado company
www.bizjournals.com - July 8 at 8:52 PM |
Aytu BioScience (NASDAQ:AYTU) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Aytu BioScience (NASDAQ AYTU) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
